355 related articles for article (PubMed ID: 26717150)
1. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
Hoffmann LS; Kretschmer A; Lawrenz B; Hocher B; Stasch JP
PLoS One; 2015; 10(12):e0145048. PubMed ID: 26717150
[TBL] [Abstract][Full Text] [Related]
2. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
Korkmaz S; Loganathan S; Mikles B; Radovits T; Barnucz E; Hirschberg K; Li S; Hegedüs P; Páli S; Weymann A; Karck M; Szabó G
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):70-7. PubMed ID: 22914857
[TBL] [Abstract][Full Text] [Related]
4. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
Chester M; Seedorf G; Tourneux P; Gien J; Tseng N; Grover T; Wright J; Stasch JP; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L755-64. PubMed ID: 21856817
[TBL] [Abstract][Full Text] [Related]
5. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
6. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
Chester M; Tourneux P; Seedorf G; Grover TR; Gien J; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2009 Aug; 297(2):L318-25. PubMed ID: 19465519
[TBL] [Abstract][Full Text] [Related]
7. Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
Harloff M; Prüschenk S; Seifert R; Schlossmann J
Br J Pharmacol; 2022 Jun; 179(11):2460-2475. PubMed ID: 33651375
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Meurer S; Pioch S; Pabst T; Opitz N; Schmidt PM; Beckhaus T; Wagner K; Matt S; Gegenbauer K; Geschka S; Karas M; Stasch JP; Schmidt HH; Müller-Esterl W
Circ Res; 2009 Jul; 105(1):33-41. PubMed ID: 19478201
[TBL] [Abstract][Full Text] [Related]
9. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
[TBL] [Abstract][Full Text] [Related]
10. Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.
Surmeli NB; Marletta MA
Chembiochem; 2012 May; 13(7):977-81. PubMed ID: 22474005
[TBL] [Abstract][Full Text] [Related]
11. Effects of soluble guanylate cyclase activation on heart transplantation in a rat model.
Loganathan S; Korkmaz-Icöz S; Radovits T; Li S; Mikles B; Barnucz E; Hirschberg K; Karck M; Szabó G
J Heart Lung Transplant; 2015 Oct; 34(10):1346-53. PubMed ID: 26210750
[TBL] [Abstract][Full Text] [Related]
12. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
Geschka S; Kretschmer A; Sharkovska Y; Evgenov OV; Lawrenz B; Hucke A; Hocher B; Stasch JP
PLoS One; 2011; 6(7):e21853. PubMed ID: 21789188
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
14. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
Korkmaz S; Radovits T; Barnucz E; Hirschberg K; Neugebauer P; Loganathan S; Veres G; Páli S; Seidel B; Zöllner S; Karck M; Szabó G
Circulation; 2009 Aug; 120(8):677-86. PubMed ID: 19667237
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide sensitive guanylyl cyclase activity decreases during cerebral postnatal development because of a reduction in heterodimerization.
Haase N; Haase T; Seeanner M; Behrends S
J Neurochem; 2010 Jan; 112(2):542-51. PubMed ID: 19895661
[TBL] [Abstract][Full Text] [Related]
17. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
[TBL] [Abstract][Full Text] [Related]
18. Changes in the nitric oxide-soluble guanylate cyclase system and natriuretic peptide receptor system in placentas of pregnant Dahl salt-sensitive rats.
Takushima S; Nishi Y; Nonoshita A; Mifune H; Hirata R; Tanaka E; Doi R; Hori D; Kamura T; Ushijima K
J Obstet Gynaecol Res; 2015 Apr; 41(4):540-50. PubMed ID: 25370989
[TBL] [Abstract][Full Text] [Related]
19. NO- and haem-independent soluble guanylate cyclase activators.
Schmidt HH; Schmidt PM; Stasch JP
Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
[TBL] [Abstract][Full Text] [Related]
20. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
